OptimizeRx Corporation (OPRX)

[COLD]

Wow. I wouldn't have guessed that. It's only a matter of time until this stock begins to move with earnest. Less than 30m shares outstanding and a market cap of about 45m. They look to be profitable in 2018. I see you follow some bio-tech stocks. Which are your favorites? I've been watching PTLA. It's been beat up long term it looks good.

[pearsby09]

I was one of the first wave of investors. I bought in at a cost basis of a dollar per share directly from the company many years ago..10 to 15, I lost track.

[COLD]

persby09,

I'm curious as to how long you've owned this stock. I remember buying a chunk through Emergeant Financial in a private placement probably 8 years at I believe $1.10. I don't know why I held on. I guess I liked the story.

[pearsby09]

You are welcome. I am very close to this company and have been in the health care industry for 30 years. The potential of this platform is still very untapped. Since their managerial changes this company even has far more potential. You are very wise to be invested in this company long term.

[COLD]

I was very impressed with the most recent conference call and I added to my position. I'm glad to hear that there are a few out there who have taken notice. I appreciate your response.

[pearsby09]

Yes, I believe this will be a 10 dollar stock within 12 to 18 months. Their applications are endless for patients with multiple disease states. Management has been recycled and the NEW management is very solid.

[COLD]

This stock looks like it's ready to go to next level. Does anybody else follow this? The quarterly conference call went extremely well.

[pearsby09]

Nice volume and price to end the week. I believe, as I am familiar with the managerial change, that this company is healthier than ever. I will not be surprised if they are bought out in 2018. They are in an excellent growing space, excellent BIG time partners, excellent EMR related product, Baby Boomers increasing prescription rate, VERY LOW operational expense and over head and excellent focused management. Please listen to some of the recent company presentations.

[gjervis]

FINALLY!!!

[gjervis]

Something is up, unusual volume.

[gjervis]

OptimizeRx (OPRX) Presents At 7th Annual LD Micro Invitational Conference - Slideshow

https://seekingalpha.com/article/4080043-optimizerx-oprx-presents-7th-annual-ld-micro-invitational-conference-slideshow

[gjervis]

$OPRX Noble Con 13 Investor Presentation

http://noble.mediasite.com/mediasite/Play/4ee7ee409e1c4b3c82028790942d56601d

Lets see how Q4 turns out.

[4retire]

I have held this stock for over seven years now. I would have made more money shorting it.

[gjervis]

I have to agree, this quarter was a dud. shareholders expressed their frustration in the CC.

[4retire]

Very poor performance during the last few quarters. Expenses continue to increase with the hiring of professionals to ramp up sales. Only problem is that sales were basically flat.

OPRX continues to try and reinvent itself over the last few years. As a long time shareholder I must say that it is very frustrating to hold on to this stock when "true profitability is just around the corner."

Sorry, that's my vent until next quarter's report card.

[gjervis]

OptimizeRx Launches New Suite of Services to Engage Healthcare Professionals

http://finance.yahoo.com/news/optimizerx-launches-suite-services-engage-123100973.html

[gjervis]

i am a buyer today, debt free cash rich with a backer like WPP and Grey Healthcare? with a 5:1 ROI on average? no fanfare, just chipping away diligently at growing the moat.

now trading at prices WPP got in? i am a buyer for sure today. Looking forward to results in a week's time.

[gjervis]

Nice ad from $OPRX

[gjervis]

OptimizeRx’s Promotional Programs Deliver Return on Investment of up to 12:1 ROI

Proven as One of the Most Effective Digital Tactics Available to Pharmaceutical Manufacturers

ROCHESTER, Mich., Oct. 18, 2016 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (OTCQB:OPRX), a health technology software company whose premier content-delivery platform enables pharmaceutical companies to offer doctors valuable product information and patient support right at point of prescribe, announced independent research results that prove the unique effectiveness and impact of OptimizeRx’s promotional platform for its clients across numerous therapeutic areas.

An image including study results is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/a8e5ef08-334a-4cd7-8fd9-6d0ccac665a6

The studies were designed to measure the impact of physicians’ prescribing changes when a copay or free trial was deemed available for a brand named medication that was being considered for ePrescribing. The studies were conducted by Cognizant and Ogilvy Analytics during 2015 and 2016 on behalf of top global pharmaceutical companies who utilized OptimizeRx to deliver their available copay and free trial vouchers with an ePrescription.

The results, along with other independent reviews, confirm that the OptimizeRx platform substantially grows total prescriptions for its promoted brands by delivering meaningful support right at point of care within its network of over 250,000 healthcare providers. In fact, OptimizeRx delivered a return on investment for each pharmaceutical brand that ranged from 300% to 1,200%.

These results are well above the traditional effects of alternate promotional or web advertising results and shows the unique value OptimizeRx’s can deliver to pharmaceutical manufacturers—as well as the highly deemed value this has on doctors who resulted in selecting and prescribing more of the brands who are willing to provide these automated patient savings right within their electronic health records (EHRs).

Doctors now spend over three hours a day using EHRs. As the leading integrator of pharma services within these EHRs, OptimizeRx provides financial and clinical messaging and support directly within the doctor’s prescribing workflow to make it easier for them to offer savings and education to help them start and stay on patients' medications.

“These results clearly show that our services, which are promoted in hundreds of EHR systems, deliver the ROI that pharmaceutical and biotech companies are striving to achieve,” said Terry Hamilton, SVP of Sales of OptimizeRx. “Our clients recognize that they need new ways to reach and support doctors who have less and less time to spend with pharmaceutical sales representatives.”

http://www.globenewswire.com/news-release/2016/10/18/880369/0/en/OptimizeRx-s-Promotional-Programs-Deliver-Return-on-Investment-of-up-to-12-1-ROI.html

[gjervis]

OptimizeRx and Allscripts Expand Partnership to Increase Focus on Clinical Messaging for Pharmaceutical Companies

ROCHESTER, Mich., Oct. 05, 2016 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (OTCQB:OPRX), a health technology software company whose premier content-delivery platform enables pharmaceutical companies to provide point of care patient-care services, has acquired all of the LogRx inventory for the remainder of 2016 and 2017 from Allscripts Healthcare, LLC (NASDAQ:MDRX), a global leader in healthcare information technology solutions. Under this expanded partnership, OptimizeRx will sell the Allscripts LogRx messaging solution.

“This expanded partnership with Allscripts extends our point of care solutions that we can bring to the medical community,” said William Febbo, CEO of OptimizeRx. “The LogRx product strongly complements our core financial messaging (eCoupon) product, and it allows us to continue to increase and diversify our revenue base. We expect this expanded partnership to have a material impact on revenue in 2017 and beyond, and we are pleased with this continued validation of our value added solutions.”

Lynn O’Connor Vos, CEO of ghg, a subsidiary of WPP, commented: “Given OptimizeRx’s continued integration into the pharmaceutical companies within WPP, this allows us to bring additional value to our collective clients as the lead aggregator of services at point of care. The continued decline of accessibility of sales representatives to Health Care Providers makes the point of care delivery of messaging critical to improving outcomes for the patients.”

[gjervis]

New Investor Presentation at Liolios 5th Annual Gateway Conference
September 7, 2016 - September 8, 2016
San Francisco, CA

http://wsw.com/webcast/liolios2/oprx/?lobby=true&day=1

[4retire]

The 10Q is out. Increase in sales but a larger increase in operating costs. I thought this was the year that OPRX would hit profitability. Seems they are going in the wrong direction. They expect operating costs to rise?????? Disappointing!

Evidently they didn't want to have a conference on these results...........

[gjervis]

Has anyone visited their website recently? seems they did an upgrade.

[gjervis]

ghg 2016

http://www.mmm-online.com/agency/ghg-2016/article/506175/

But while one imagines Vos is not upset about any of these developments, she is most enthusiastic when discussing broader health-marketing trends and the opportunities she expects to emerge from them. Take ghg's ambitions to be the agency world's preeminent point-of-care player. Armed with a belief that the POC suite is undergoing seismic change, ghg has invested heavily in a handful of companies and tools. Perhaps the most notable is OptimizeRx, the minds behind a content-delivery platform that helps drugmakers provide on-demand services within the EHR context.

“Right now, what's being delivered on OptimizeRx is financial assistance,” Vos explains. “When doctors have patients in the office, they can touch on a brand and find out right away if financial assistance is available — and if so, [the offer] goes straight to the pharmacy.”

[gjervis]

Hiring is a good sign.

[gjervis]

yup,

requires serious patience with this one. at least every quarter they are improving with the business. just need to see this go to the bottom line in revenue growth increasing

[4retire]

Up over four times the normal volume and we're up a whopping $.01. Pathetic.

[gjervis]

OptimizeRx (OTCQB:OPRX): Q1 EPS of -$0.01 beats by $0.02.Revenue of $1.76M (+18.1% Y/Y) beats by $0.06M.

http://seekingalpha.com/pr/16481843-optimizerx-corporation-reports-first-quarter-2016-results

[gjervis]

OptimizeRx and RxWiki Partner to Bring Mobile Co-Pay Coupons to Network of 1,300 Community Pharmacies

http://finance.yahoo.com/news/optimizerx-rxwiki-partner-bring-mobile-123100911.html

[gjervis]

Updated Merriman Report, still $2.00 price target

http://www.optimizerxcorp.com/investors/OPRX_BUY_3_28_16.pdf

[gjervis]

Or for an Enterprise value of $1.05 - $0.28 (cash) = $0.77/share.

[4retire]

looks like you got more at $1.05/share

[gjervis]

Bought more OPRX

[gjervis]

100% Upside maintained in Sell Side report http://www.optimizerxcorp.com/investors/OPRX_BUY_3_18_16.pdf

[gjervis]

OPRX Presented at the ROTH Capital Conference today http://wsw.com/webcast/roth30/oprx/

[gjervis]

OptimizeRx Corporation Reports Record Fourth Quarter and Full Year 2015 Results http://finance.yahoo.com/news/optimizerx-corporation-reports-record-fourth-200100519.html

[gjervis]

TrialCard Announces Partnership with OptimizeRx

http://www.prweb.com/releases/2016/02/prweb13226027.htm

Pharmaceutical services provider TrialCard announced today that it has entered into a partnership with OptimizeRx (OTCQB:OPRX) to integrate its coupon and co-pay offerings with OptimizeRx electronic health record (EHR) technology. OptimizeRx, which has partnerships that reach over 350 EHRs, will provide TrialCard with a platform to distribute patient savings offers on behalf of its pharmaceutical manufacturer clients. Estimates project that electronic prescribing volume could be as high as 2 billion prescriptions in 2016, and a 2012 Atlantic Information Services, Inc. study indicated that 80% of physicians were more likely to prescribe a drug with a co-pay savings card.
“EHR represents a very important distribution channel for our clients,” said TrialCard President and CEO Mark Bouck. “By forging a partnership with OptimizeRx and capitalizing on their expansive reach we’re making it significantly easier for manufacturers to offer a financial savings vehicle to patients at the point of prescribing.”
Pharmaceutical manufacturers that are currently partnering with TrialCard will now be able to incorporate the OptimizeRx service offering into their co-pay savings program.
About TrialCard Incorporated
TrialCard Incorporated provides product access, medication adherence, and patient support services on behalf of pharmaceutical manufacturers. Founded in 2000, TrialCard has become the largest provider of patient access programs in the industry, processing over $1 billion in reimbursement benefits per year. TrialCard holds nine US patents related to the processing and marketing of patient access programs. The company is headquartered in Cary, North Carolina. For more information about TrialCard, please visit http://www.trialcard.com.
About OptimizeRx
OptimizeRx Corporation (OTCQB: OPRX) provides unique consumer and physician platforms to help patients better afford and comply with their medicines and healthcare products, while offering pharmaceutical and healthcare companies effective ways to expand awareness, access and adherence to their medications. OptemizeRx’s core product, SampleMD, replaces drug samples with electronic trial vouchers and copay coupon savings that are electronically added to an e-Prescription and sent electronically to the pharmacy and is integrated within leading Electronic Health Record (EHR) platforms in the country, including Allscripts, Quest Diagnostics, Practice Fusion and over 350 other EHRs to reach over 250,000 healthcare providers. In turn, we promote patient savings and support from the world’s largest pharmaceutical companies, including Pfizer, Lilly, Novartis, AstraZeneca and many others. For more information, please go to http://www.optimizerxcorp.com.

[4retire]

New CEO. Thank goodness. Harrel was a smart and likeable guy but I think his second job was impersonating a cadaver. He was so lacking personality in his calls and probably in his institutional presentations

[gjervis]

New Corporate profile for $OPRX http://www.optimizerxcorp.com/investors/OPRX_Corporate_Profile_012016.pdf

[gjervis]

think it was block trades, one trade was 200,000 and another was 250,000. if you take that out of the total trade, you would see it was a normal trading day.

[4retire]

Weird! Almost half a million shares (about 13 times normal volume) and no price per share movement.

[gjervis]

No complaints from me. i will happily take what i can get. i hope it falls more.

[4retire]

Kind of sad that a 2,000 share sale can plummet the price by 6.25%.

[gjervis]

First Movers and networking effect http://www.optimizerxcorp.com/liolios.html

[gjervis]

Most recent presentation of OPRX at the LMicro Conference. http://wsw.com/webcast/ldmicro9/oprx/

[gjervis]

This had to be block trades. no way could this amount of shares be traded naturally in this company.

[gjervis]

Haven't seen open market buying in a long time https://www.insidertracking.com/company?ticker=OPRX

[4retire]

A couple of analysts were in the $3 to $4 range months ago.

[Wolfberry]

Analyst forecasting 2.00

[Wolfberry]

WPP buying 20% is "BIG " news. Analyst forecasting $2.00